NCT01687595View on ClinicalTrials.gov

Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 29, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

January 31, 2015

Conditions
Herpes Simplex Type 2
Interventions
DRUG

HerpV and QS-21

HerpV (recombinant human heat shock protein 70 \[rh-Hsc70\] polyvalent peptide complex) in combination with adjuvant QS-21

DRUG

Placebo

phosphate buffered saline

Trial Locations (5)

77030

Center for Clinical Studies - Texas Medical Center, Houston

77065

Center for Clinical Studies - Cypress, Houston

77598

Center for Clinical Studies- Webster, Houston

97210

Westover Heights Clinic, Portland

98104

University of Washington Virology Research Clinic, Seattle

Sponsors

Lead Sponsor

Agenus Inc.
All Listed Sponsors
lead

Agenus Inc.

INDUSTRY

NCT01687595 - Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes | Biotech Hunter | Biotech Hunter